Zynerba Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2007-01-01
- Employees
- 27
- Market Cap
- -
- Website
- http://www.zynerba.com
Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome
- First Posted Date
- 2021-12-08
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Zynerba Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05149898
- Locations
- 🇺🇸
Greenwood Genetic Center, Greenville, South Carolina, United States
🇦🇺Lady Cilento Children's Hospital - South Brisbane, Brisbane, Queensland, Australia
🇦🇺Genetics Clinics Australia, Melbourne, Victoria, Australia
Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome
- Conditions
- Fragile X Syndrome
- Interventions
- Drug: PlaceboDrug: ZYN002 - transdermal gel
- First Posted Date
- 2021-07-27
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Zynerba Pharmaceuticals, Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT04977986
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Science 37, Culver City, California, United States
🇺🇸Amnova Clinical Research, LLC, Irvine, California, United States
Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS
- Conditions
- Fragile X Syndrome
- Interventions
- Drug: ZYN002 - Cannabidiol Transdermal Gel
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Zynerba Pharmaceuticals, Inc.
- Target Recruit Count
- 550
- Registration Number
- NCT03802799
- Locations
- 🇺🇸
Science 37, Culver City, California, United States
🇺🇸Amnova Clinical Research, LLC, Irvine, California, United States
🇺🇸UC Davis Health System, MIND Institute, Sacramento, California, United States
Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX)
- Conditions
- Fragile X Syndrome
- Interventions
- Drug: ZYN002 - Cannabidiol Transdermal GelOther: Placebo Transdermal Gel
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Zynerba Pharmaceuticals, Inc.
- Target Recruit Count
- 212
- Registration Number
- NCT03614663
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸UC Davis Health System, MIND Institute, Sacramento, California, United States